Scarica l'app Stockscreener
0.868
2.63%
-0.0234
Dopo l'orario di chiusura:
.87
0.002
+0.23%
Precedente Chiudi:
$0.8914
Aprire:
$0.86
Volume 24 ore:
1.04M
Relative Volume:
1.01
Capitalizzazione di mercato:
$77.56M
Reddito:
-
Utile/perdita netta:
$-23.49M
Rapporto P/E:
-2.5255
EPS:
-0.3437
Flusso di cassa netto:
$-24.59M
1 W Prestazione:
-19.63%
1M Prestazione:
-18.11%
6M Prestazione:
-39.30%
1 anno Prestazione:
+110.22%
Intervallo 1D:
$0.8201
$0.8832
Intervallo di 1 settimana:
$0.5501
$1.07
Portata 52W:
$0.2223
$3.83
Cognition Therapeutics Inc Stock (CGTX) Company Profile
Nome
Cognition Therapeutics Inc
Settore
Industria
Telefono
412-481-2210
Indirizzo
2500 WESTCHESTER AVE, PURCHASE
Compare CGTX vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CGTX
Cognition Therapeutics Inc
|
0.868 | 77.56M | 0 | -23.49M | -24.59M | -0.3437 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Cognition Therapeutics Inc Stock (CGTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-19 | Aggiornamento | B. Riley Securities | Neutral → Buy |
| 2024-07-30 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2021-11-03 | Iniziato | B. Riley Securities | Buy |
| 2021-11-03 | Iniziato | Oppenheimer | Outperform |
Cognition Therapeutics Inc Borsa (CGTX) Ultime notizie
CGTX Technical Analysis & Stock Price Forecast - Intellectia AI
CGTX Should I Buy - Intellectia AI
Cognition Therapeutics plans late-stage trial for dementia drug By Investing.com - Investing.com Australia
Cognition Therapeutics plans late-stage trial for dementia drug - Investing.com
Cognition Therapeutics CEO Issues Letter to Shareholders - globenewswire.com
Q1 Earnings Forecast for CGTX Issued By HC Wainwright - MarketBeat
Here's Why We're Watching Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Situation - Sahm
Cognition Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Cognition Therapeutics (NASDAQ:CGTX) Receives Buy Rating from Chardan Capital - MarketBeat
Cognition Therapeutics posts narrower 2025 loss, eyes DLB trial By Investing.com - Investing.com South Africa
Cognition Therapeutics Reports 2025 Financial Results and Advances Zervimesine for DLB Psychosis and Alzheimer’s Clinical Trials - minichart.com.sg
Cognition Therapeutics Inc (CGTX) Q4 2025 Earnings Call Highlights: Promising Developments in ... By GuruFocus - Investing.com Canada
Cognition Therapeutics Advances Zervimesine (CT1812) for Alzheimer’s and Dementia—Clinical Results, Pipeline, and Strategic Overview - minichart.com.sg
Cognition Therapeutics Highlights 2025 Results, Zervimesine Progress - TipRanks
Cognition Therapeutics Q4 2025 Earnings Call Transcript - MarketBeat
Earnings Call Summary | Cognition Therapeutics(CGTX.US) Q4 2025 Earnings Conference - 富途牛牛
Cognition Therapeutics Q4 Earnings Call Highlights - MarketBeat
Cognition Therapeutics (NASDAQ:CGTX) Posts Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat
Earnings call transcript: Cognition Therapeutics Q4 2025 shows reduced losses - Investing.com
Cognition Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
CGTX: Zervimesine advances toward DLB psychosis registration, with strong data and solid cash position - TradingView
Earnings call transcript: Cognition Therapeutics Q4 2025 shows reduced losses By Investing.com - Investing.com South Africa
CGTX: Zervimesine advances for DLB psychosis with strong data, regulatory focus, and improved 2025 financials - TradingView
Cognition Therapeutics posts narrower 2025 loss, eyes DLB trial - Investing.com
COGNITION THERAPEUTICS ($CGTX) Releases Q4 2025 Earnings - Quiver Quantitative
Cognition Therapeutics 10-K: Net loss $23.5M, EPS $(0.32) - TradingView
Zervimesine pipeline and grant backing at Cognition (NASDAQ: CGTX) - Stock Titan
Cognition Therapeutics (NASDAQ: CGTX) narrows 2025 loss, funds into Q2 2027 - Stock Titan
Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update - The Manila Times
Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical ... - Caledonian Record
Cognition Therapeutics (CGTX) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Cognition Therapeutics Inc expected to post a loss of 8 cents a shareEarnings Preview - TradingView
Zervimesine Demonstrates Symptom Slowing in Phase 2 SHIMMER Trial for Dementia With Lewy Bodies - Neurology Live
Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results - The Globe and Mail
Cognition presents data on dementia drug zervimesine at conference By Investing.com - Investing.com South Africa
CGTX PE Ratio & Valuation, Is CGTX Overvalued - intellectia.ai
Cognition presents data on dementia drug zervimesine at conference - Investing.com
Cognition Therapeutics Presents Evidence of Zervimesine's Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026 - Bitget
Cognition Therapeutics Presents Promising Phase 2 Results of Zervimesine for Dementia with Lewy Bodies at AD/PD 2026 Conference - Quiver Quantitative
Cognition Therapeutics Presents Evidence of Zervimesine’s - GlobeNewswire
Cognition Therapeutics (CGTX) Stock Analysis Report | Financials & Insights - Benzinga Japan
Aug Intraday: Can Cognition Therapeutics Inc lead its sector in growthQuarterly Risk Review & Safe Entry Point Identification - baoquankhu1.vn
MACD Signal: What is the dividend yield of Cognition Therapeutics IncDividend Hike & AI Based Trade Execution Alerts - baoquankhu1.vn
Cognition Therapeutics shifts focus to DLB psychosis treatment By Investing.com - Investing.com Australia
Cognition Therapeutics shifts focus to DLB psychosis treatment - Investing.com Nigeria
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Cognition Therapeutics Advancing Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) Psychosis - Bitget
Cognition Therapeutics Advances Zervimesine for DLB Psychosis - TipRanks
Cognition Therapeutics, Inc. Announces Advancement of Zervimesine Development for Dementia with Lewy Bodies Psychosis Treatment - Quiver Quantitative
Cognition Therapeutics Inc Azioni (CGTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):